Huddinge - Medivir AB (OMX: MVIR), the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear®, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe. Xerclear® will be marketed under the trade name Zoviduo and Zovirax Duo in Europe.

In June 2010, Medivir entered an agreement with GSK, which granted GSK exclusive rights to market and distribute Xerclear® for non-prescription (OTC) sales in several markets, including Europe, Russia, Japan, India, Australia and New Zealand.

GSK has now kicked off the first wave of launches in the five countries where Zoviduo/Zovirax Duo is approved for OTC sales: Denmark, Czech Republic, Slovakia, Portugal and Poland. The launches will take place during the spring, beginning in February. GSK’s goal is to launch the product in the remaining markets in Europe as the respective regulatory...